Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABBV-155 · 1 trial · 1 indication
The Maximum Tolerated Dose (MTD) and/or the Recommended Phase Two Dose (RPTD) of ABBV-155 will be determined during the dose escalation phase (Part 1).
ORR is defined as the percentage of participants with documented best response partial response (PR) or better according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
| Arm | Type | Description |
|---|---|---|
| Escalation 1a: ABBV-155 | EXPERIMENTAL | Participants will be administered ABBV-155 (various doses). |
| Escalation 1b: ABBV-155 + paclitaxel or docetaxel | EXPERIMENTAL | Participants will be administered ABBV-155 (various doses) in combination with paclitaxel or docetaxel . |
| Expansion 2a: ABBV-155 in SCLC | EXPERIMENTAL | Description: Participants with small cell lung cancer (SCLC) will administer ABBV-155 (at the recommended Phase 2 dose). |
| Expansion 2b: ABBV-155 + paclitaxel in Breast Cancer | EXPERIMENTAL | Participants with breast cancer will be administered ABBV-155 (at the recommended Phase 2 dose identified for combination with paclitaxel in part 1b) in combination with paclitaxel. |
| Expansion 2b: ABBV-155 + docetaxel in NSCLC | EXPERIMENTAL | Participants with non-small cell lung cancer (NSCLC) will be administered ABBV-155 (at or near the recommended Phase 2 dose identified for combination with paclitaxel in part 1b) in combination with docetaxel. |
| Name | Type | Description |
|---|---|---|
| ABBV-155 | DRUG | Intravenous (IV) Infusion |
| Paclitaxel | DRUG | Intravenous (IV) Infusion |
| Docetaxel | DRUG | Intravenous (IV) Infusion |
Inclusion Criteria: * Has a histologic or cytologic diagnosis of a malignant solid tumor. * Participants enrolled in Part 2a (monotherapy, dose expansion) must have small cell lung cancer (SCLC) diagnosis; participants enrolled to Part 2b (combination therapy, dose expansion) must have either NSCLC...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
ABBV-155 is an investigational small molecule developed by AbbVie Inc. (ticker ABBV) for the treatment of advanced solid tumors. It is designed to target BCL-xL and has been studied in a Phase 1 clinical trial. It is not approved for any indication and remains in clinical development.
ABBV-155 is being studied for use in adults with advanced solid tumors, including relapsed and refractory disease. The Phase 1 trial evaluated it both as a single agent and in combination with taxane therapy. It is investigational and has not been approved for any use.
ABBV-155 targets BCL-xL, a protein involved in regulating cell survival. By inhibiting BCL-xL, the drug is intended to promote apoptosis, or programmed cell death, in tumor cells. This mechanism is being explored in advanced solid tumors.
ABBV-155 is being developed by AbbVie Inc., which trades under the ticker ABBV. AbbVie sponsored the Phase 1 clinical trial of the drug in advanced solid tumors. No other developers or partners are identified for this asset.
ABBV-155 is in Phase 1 clinical development. Its single trial, NCT03595059, has been completed. The drug is investigational and has not received FDA approval. No active trials are currently listed for ABBV-155.
ABBV-155 was studied in one Phase 1 trial, NCT03595059, titled a study with ABBV-155 alone and in combination with taxane therapy in adults with relapsed and/or refractory solid tumors. The trial enrolled 168 patients across the United States, Australia, Canada, Israel, Japan, Netherlands, Puerto Rico, South Korea, Spain, and Taiwan, and is completed.